23 completed, 8 recruiting, 2 terminated, 2 unknown. 36 Phase 1, 9 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 36 | Completed 23, Recruiting 8, Terminated 2, Unknown 2, Not yet recruiting 1 |
| Phase 2 | 9 | Recruiting 5, Completed 2, Not yet recruiting 1, Terminated 1 |
Follow Vulvar Neoplasms: new trials by email Literature Review of Vulvar Neoplasms trials Research Report on Vulvar Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers E7 TCR-T cells, Aldesleukin - HPV-Associated Cervical Carcinoma, HPV-Related Carcinoma | Phase 1 / Phase 2 | Recruiting | Christian Hinrichs | 15 | 2025-08-11 | 2026-10-28 |
| Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors YH32364 - EGFR Overexpression, Locally Advanced Solid Tumor | Phase 1 / Phase 2 | Recruiting | Yuhan Corporation | 80 | 2025-06-12 | 2026-06-10 |
| Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor Carbon Nanoparticle-Loaded Iron [CNSI-Fe], Carbon Nanoparticle-Loaded Iron - Tumor, Solid, Lung Cancer | Phase 1 / Phase 2 | Recruiting | Sichuan Enray Pharmaceutical Sciences Company | 54 | 2024-11-12 | 2026-02-25 |
| Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma SCG142, Cyclophosphamide, Fludarabine - HPV-Related Squamous Cell Carcinoma, HPV-Related Cervical Squamous Cell Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | SCG Cell Therapy Pte. Ltd. | 66 | 2024-10-01 | 2024-07-17 |
| A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors INCB099280, axitinib - Advanced Solid Tumors | Phase 1 / Phase 2 | Terminated | Incyte Corporation | 5 | 2024-04-16 | 2026-06-04 |
| HRYZ-T101 Injection for HPV18 Positive Solid Tumor HRYZ-T101 Injection, Fludarabine + Cyclophosphamide - Cervical Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1 | Recruiting | HRYZ Biotech Co. | 32 | 2023-11-01 | 2024-02-02 |
| SCG142 TCR-T Cells for Human Papillomavirus-Associated Carcinomas SCG142 TCR-T cells - Human Papillomavirus Associated Carcinomas, Cervical Cancer | Phase 1 | Recruiting | The Affiliated Hospital of Qingdao University | 18 | 2023-08-02 | 2024-08-09 |
| HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor Fludarabine + Cyclophosphamide, HRYZ-T101 TCR-T Cell - Cervical Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1 | Unknown | HRYZ Biotech Co. | 17 | 2023-03-21 | 2024-02-02 |
| A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere) - Advanced Solid Tumors, Genital Neoplasm, Female | Phase 1 / Phase 2 | Recruiting | Marengo Therapeutics, Inc. | 366 | 2023-01-04 | 2026-08-11 |
| Carbon Nanoparticle-Loaded Iron [CNSI-Fe(II)] in the Treatment of Advanced Solid Tumor CNSI-Fe(II) 30 mg, CNSI-Fe(II) 60 mg, CNSI-Fe(II) 90 mg - Advanced Solid Tumor, Lung Cancer | Phase 1 | Completed | Sichuan Enray Pharmaceutical Sciences Company | 19 | 2022-11-17 | 2025-08-03 |
| A Study for Assessing the Efficacy and Safety of Tetrahydrobiopterin in Radiation-Induced Skin Injury Tetrahydrobiopterin - Radiation-Induced Dermatitis | Phase 1 | Unknown | West China Second University Hospital | 45 | 2022-03-01 | 2022-02-28 |
| Safety, Tolerability and Pharmacokinetics Investigation of Stimotimagene Copolymerplasmid Stimotimagene copolymerplasmid, Ganciclovir - Sarcoma, Melanoma | Phase 1 | Completed | Gene Surgery LLC | 21 | 2022-01-01 | 2024-07-01 |
| Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types Atezolizumab, Tivozanib - Bile Duct Cancer, Gall Bladder Cancer | Phase 1 / Phase 2 | Recruiting | University of Florida | 29 | 2021-12-07 | 2026-07-13 |
| A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers Bintrafusp Alfa, PDS01ADC, Entinostat - Oropharyngeal Cancer, Neck Cancer | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 55 | 2021-10-05 | 2026-09-22 |
| Nelfinavir, Cisplatin, and External Beam Radiation Therapy for the Treatment of Locally Advanced Vulvar Cancer That Cannot Be Removed by Surgery Cisplatin, External Beam Radiation Therapy, Nelfinavir - Stage II Vulvar Cancer AJCC v8, Stage III Vulvar Cancer AJCC v8 | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 25 | 2020-08-07 | 2026-11-10 |
| A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli), Recombinant nonavalent Human Papillomavirus (Types 6,11,16,18,31,33,45,52,58) Vaccine - Human Papillomavirus Infection | Phase 1 | Completed | Beijing Health Guard Biotechnology, Inc | 160 | 2019-09-01 | 2023-01-17 |
| Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females 9-valent HPV Recombinant Vaccine, Placebo - Cervical Cancers, Vulvar Cancer | Phase 1 | Completed | Shanghai Bovax Biotechnology Co., Ltd. | 90 | 2018-10-10 | 2020-01-22 |
| Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers Durvalumab, Laboratory Biomarker Analysis, Stereotactic Radiosurgery - Advanced Cervical Adenocarcinoma, Advanced Vaginal Carcinoma | Phase 1 | Completed | M.D. Anderson Cancer Center | 20 | 2018-07-18 | 2023-09-13 |
| A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors XmAb20717 - Melanoma, Breast Carcinoma | Phase 1 | Completed | Xencor, Inc. | 150 | 2018-07-10 | 2022-12-01 |
| Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer Durvalumab, Tremelimumab, Radiation Therapy - Recurrent Gynecological Cancer, Metastatic Cervical Cancer | Phase 1 | Terminated | Dana-Farber Cancer Institute | 16 | 2018-06-01 | 2025-05-31 |
Showing 20 of 36. Sign in to see all of them.
Uterine Cervical Neoplasms (32) · Vaginal Neoplasms (25) · Anus Neoplasms (17) · Penile Neoplasms (15) · Endometrial Neoplasms (14) · Fallopian Tube Neoplasms (12) · Carcinoma, Ovarian Epithelial (11) · Breast Neoplasms (9) · Neoplasms (9) · Prostatic Neoplasms (9) · Carcinoma, Hepatocellular (8) · Squamous Cell Carcinoma of Head and Neck (8) · Urinary Bladder Neoplasms (8) · Bile Duct Neoplasms (7)
Female Urogenital Diseases (36) · Female Urogenital Diseases and Pregnancy Complications (36) · Genital Diseases (36) · Genital Diseases, Female (36) · Urogenital Diseases (36) · Genital Neoplasms, Female (35) · Neoplasms by Site (35) · Urogenital Neoplasms (35) · Vulvar Diseases (34) · Uterine Cervical Diseases (33) · Uterine Diseases (33) · Uterine Neoplasms (31) · Neoplasms (27) · Vaginal Diseases (25) · Digestive System Diseases (24)
Cyclophosphamide (4) · fludarabine (4) · Cisplatin (2) · Docetaxel (2) · Radiosurgery (2) · Radiotherapy (2) · Trastuzumab (2) · aflibercept (2) · aldesleukin (2) · durvalumab (2) · entinostat (2) · tremelimumab (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (1) · Acetaminophen (1)
National Cancer Institute (NCI) (6) · HRYZ Biotech Co. (2) · M.D. Anderson Cancer Center (2) · Regeneron Pharmaceuticals (2) · Sichuan Enray Pharmaceutical Sciences Company (2) · Abramson Cancer Center at Penn Medicine (1) · Alliance for Clinical Trials in Oncology (1) · Beijing Health Guard Biotechnology, Inc (1) · Case Comprehensive Cancer Center (1) · Christian Hinrichs (1) · Dana-Farber Cancer Institute (1) · Gene Surgery LLC (1) · Incyte Corporation (1) · Marengo Therapeutics, Inc. (1) · Masonic Cancer Center, University of Minnesota (1)
United States (21) · China (8) · Canada (2) · France (1) · Germany (1) · Russia (1) · South Korea (1) · Spain (1) · United Kingdom (1)
Jian Zhang, Doctor (2) · Lilie L Lin (2) · William P. Tew, MD (2) · Anthony W. Tolcher, MD (1) · Barry L. Gause, MD (1) · Charles Erlichman, MD (1) · Charles Kunos (1) · Christian S Hinrichs, MD (1) · Daniel H. Sterman, MD (1) · Franco M. Muggia, MD (1) · Hoyoung M Maeng, M.D. (1) · Irina Alekseenko (1) · Leighton Elliott, MD (1) · Levi S. Downs, MD (1) · Martin King, MD, PhD (1)
PMID 19949018, PMID 22002018, PMID 20068553, PMID 28596000, PMID 28744123, PMID 29186019, PMID 30184767, PMID 32510916, PMID 33558725, PMID 34766118, PMID 36399037, PMID 40273550, PMID 42249319, PMID 42816483
2023 (2), P30CA016087 (1), P30CA043703 (1), U01CA062502 (1), U01CA076576 (1), U01CA076642 (1)